In vitro evaluation of tenofovir disproxil fumarate (TDF) and tenofovir alafenamide (TAF) revealed comparable antiviral effects with respect to the tenofovir-diphosphate (TFV-DP) level in human peripheral blood mononuclear cells (PBMCs), despite the EC₅₀ values determined based on prodrug concentrations were nearly two orders of magnitude apart. In vivo EC₅₀ obtained from meta-analyses were in good agreement with the in vitro results, indicating intracellular TFV-DP can be employed for in vitro-in vivo translation of viral inhibition for tenofovir prodrugs. Current analysis indicated that the intracellular concentrations of TFV-DP achieving maximal antiviral effect in vitro can be directly translatable in the clinic to accomplish maximal viral load suppression attainable by tenofovir-prodrugs.

富诺酸替诺福韦酯（TDF）和替诺福韦阿拉芬酰胺（TAF）的体外评估显示，尽管确定的EC ₅₀值为基础，但人类外周血单核细胞（PBMC）中的替诺福韦二磷酸（TFV-DP）水平具有可比的抗病毒作用前药的浓度相差近两个数量级。体内EC ₅₀从荟萃分析获得的结果与体外结果高度吻合，表明细胞内TFV-DP可用于替诺福韦前药的病毒抑制作用的体外-体内翻译。目前的分析表明，在体外达到最大抗病毒作用的TFV-DP的细胞内浓度可在临床上直接翻译，以实现替诺福韦前药可实现的最大病毒载量抑制。